13F HOLDINGS REPORT (Amended)
Athyrium Capital Management, LP
Quarter ended Q2 2023 · Filed May 16, 2023 · Accession 0001123292-23-000059
Total Value
$279.1M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Amryt Pharma PLC | 03217L106 | 8,857,268 | $129.1M | 46.27% |
| 2 | Biora Inc. | 74319FAB3 | 103,500,000 | $58.1M | 20.81% |
| 3 | Omeros Corp | OMER | 65,136,000 | $46.5M | 16.66% |
| 4 | RVL PHARMACEUTICALS PLC | G6S41R101 | 14,600,444 | $16.6M | 5.96% |
| 5 | Omeros Corp | OMER | 11,005,000 | $11.1M | 3.98% |
| 6 | Paratek Pharmaceuticals Inc. | 699374AB0 | 9,000,000 | $7.4M | 2.66% |
| 7 | PUMA BIOTECHNOLOGY INC | PBYI | 1,792,114 | $5.5M | 1.98% |
| 8 | Biora Inc. | 74319F305 | 1,694,481 | $4.7M | 1.68% |